The French deeptech startup, founded at the end of 2023, aims to revolutionize cosmetic personalization thanks to the world’s first instant point-of-sale skin microbiome measurement solution.

To this end, the company specializing in in vitro skin microbiome analysis, has secured EUR 3.6 million in funding. The round—led by Remora Biotech, Paris Business Angels, Angels Santé, and several strategic business angels—will support the industrialization of Byome Derma, a simple, ultra-fast skin test that can be performed at the point of sale to recommend personalized skincare products based on each individual’s unique microbiome.

Personalized skincare recommendations

Using antigenic strips similar to COVID tests, the new test allows skin microbiome sampling and microbial diversity analysis within minutes—directly at the point of sale, without devices, without pain, and at an affordable cost, according to the company. Then a dermatologist-trained AI produces personalized skincare recommendations.

The Byome Derma test was designed to integrate as a white-label solution within retail environments, allowing cosmetic and dermo-cosmetic brands to deliver a hyper-personalized customer experience validated by robust scientific data.

Byome Derma targets both mass-market brands aiming to democratize personalization and ultra-premium beauty houses focused on customer experience, service, and loyalty. The company is currently co-developing this solution with several French and international skincare brands.

According to the company, when integrating Byome Derma at the point of sale, brands gain a powerful lever to match the right product to the right customer, enhance the retail experience with a high-value-added service, while feeding their R&D with a unique microbiome database.

Industrial production

According to the company, the financing will enable the industrial production of the first Byome Derma kits by the end of 2025, followed by international rollout in Europe, the United States, and Asia starting in 2026. Byome Labs also plans to expand its R&D team in 2026.

« Scientific innovation only matters if it can serve the many. With this fundraising, we are scaling up to the industrial level and offering brands a new standard of instant skincare recommendations, based on biological data rather than guesswork » said David Suissa, Founder & CEO of Byome Labs.

Founded at the end of 2023, Byome Labs relies on: a state-of-the-art in vitro microbiology lab, with 5,000 microbiomes sequenced and more than 200 cosmetic products tested and indexed; an R&D center, and a team of 17 experts (microbiologists, biochemists, data scientists, engineers, marketing and regulatory specialists); a unique strain collection, including yeasts and bacteria in both biofilm and planktonic forms; and a proprietary AI that matches microbial profiles with product compatibility.